Published in Proc Natl Acad Sci U S A on February 27, 2012
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol (2013) 2.41
Pre-mRNA splicing in disease and therapeutics. Trends Mol Med (2012) 2.23
The unstable repeats--three evolving faces of neurological disease. Neuron (2013) 1.26
RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci (2012) 1.07
MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res (2014) 1.00
Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem (2013) 0.98
Diagnostic odyssey of patients with myotonic dystrophy. J Neurol (2013) 0.97
Reducing levels of toxic RNA with small molecules. ACS Chem Biol (2013) 0.96
The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep (2014) 0.95
Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise. Hum Mol Genet (2012) 0.95
Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol (2015) 0.92
Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int J Biochem Cell Biol (2013) 0.91
Structure of the myotonic dystrophy type 2 RNA and designed small molecules that reduce toxicity. ACS Chem Biol (2013) 0.90
Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol (2013) 0.88
Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1. J Med Chem (2013) 0.88
Antisense therapy in neurology. J Pers Med (2013) 0.87
Myotonic dystrophy: is a narrow focus obscuring the rest of the field? Curr Opin Neurol (2012) 0.86
Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. Nucleic Acids Res (2015) 0.86
Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids (2013) 0.85
Small-molecule-mediated cleavage of RNA in living cells. Angew Chem Int Ed Engl (2012) 0.84
Treatment of type 1 myotonic dystrophy by engineering site-specific RNA endonucleases that target (CUG)(n) repeats. Mol Ther (2013) 0.83
Smaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy. PLoS Genet (2013) 0.83
Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides. ACS Chem Biol (2014) 0.82
Generation of neural cells from DM1 induced pluripotent stem cells as cellular model for the study of central nervous system neuropathogenesis. Cell Reprogram (2013) 0.82
Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1. J Pharmacol Exp Ther (2015) 0.82
Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci Rep (2013) 0.81
Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum Mol Genet (2014) 0.80
Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther (2013) 0.80
Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet (2015) 0.80
Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells. Stem Cells (2015) 0.80
RNA-Binding Proteins: Splicing Factors and Disease. Biomolecules (2015) 0.80
Cell membrane integrity in myotonic dystrophy type 1: implications for therapy. PLoS One (2015) 0.79
Biological Efficacy and Toxicity of Diamidines in Myotonic Dystrophy Type 1 Models. J Med Chem (2015) 0.78
Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models. Cell Rep (2015) 0.77
Dynamic changes of nuclear RNA foci in proliferating DM1 cells. Histochem Cell Biol (2015) 0.76
Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I. J Biol Chem (2016) 0.76
Drug discovery: Kill the messenger where it lives. Nature (2012) 0.75
Tracks through the genome to physiological events. Exp Physiol (2015) 0.75
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs (2015) 0.75
Myotonic dystrophy: approach to therapy. Curr Opin Genet Dev (2017) 0.75
Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a useful tool in myotonic dystrophy type 1. Eur J Histochem (2015) 0.75
Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila. Sci Rep (2016) 0.75
Reduction of Huntington's Disease RNA Foci by CAG Repeat-Targeting Reagents. Front Cell Neurosci (2017) 0.75
miR-93 regulates Msk2-mediated chromatin remodelling in diabetic nephropathy. Nat Commun (2016) 0.75
Dystrophia myotonica type 1 presenting with dysarthria: A case report and literature review. Exp Ther Med (2017) 0.75
Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 12.74
Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science (1998) 6.67
Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J (2000) 6.56
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol (2010) 4.86
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem (1993) 3.70
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell (2007) 3.26
Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci U S A (1997) 3.18
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A (2000) 3.04
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A (1988) 2.98
Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res (2002) 2.58
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48
Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet (1996) 2.47
Enzyme from calf thymus degrading the RNA moiety of DNA-RNA Hybrids: effect on DNA-dependent RNA polymerase. Science (1969) 2.41
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol (2009) 2.36
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans (2009) 2.32
Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A (1991) 2.22
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet (2005) 2.07
Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A (2008) 1.94
Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol (2002) 1.48
Temporally controlled targeted somatic mutagenesis in skeletal muscles of the mouse. Genesis (2005) 1.32
Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther (2000) 1.28
Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J Biol Chem (2004) 1.22
Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem (1996) 1.22
In vivo discovery of a peptide that prevents CUG-RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy models. Proc Natl Acad Sci U S A (2011) 1.22
Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol (2011) 1.09
Variation of CTG-repeat number of the DMPK gene in muscle tissue. Neuromuscul Disord (1997) 0.81
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
Pre-mRNA splicing and human disease. Genes Dev (2003) 9.13
The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell (2010) 8.66
Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet (2007) 7.42
MicroRNA-143 regulates adipocyte differentiation. J Biol Chem (2004) 6.78
Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci (2011) 6.01
Regulating gene expression through RNA nuclear retention. Cell (2005) 5.58
Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol (2002) 4.73
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
RNA-mediated neuromuscular disorders. Annu Rev Neurosci (2006) 4.24
Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell (2002) 4.05
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature (2011) 4.04
Muscleblind proteins regulate alternative splicing. EMBO J (2004) 4.01
Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat Genet (2008) 3.78
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 3.40
A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A (2008) 3.33
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2002) 3.32
Functional consequences of developmentally regulated alternative splicing. Nat Rev Genet (2011) 3.27
Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell (2007) 3.26
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron (2013) 3.25
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet (2008) 3.24
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev (2010) 3.02
Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest (2006) 3.00
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A (2013) 2.95
Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci (2012) 2.93
Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med (2013) 2.89
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet (2005) 2.59
Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med (2011) 2.56
The pathobiology of splicing. J Pathol (2010) 2.52
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol (2013) 2.43
Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans (2009) 2.32
Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J Cell Sci (2005) 2.31
Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol (2007) 2.29
Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing. Mol Cell (2002) 2.27
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Pre-mRNA splicing in disease and therapeutics. Trends Mol Med (2012) 2.23
Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest (2007) 2.14
Identification of putative new splicing targets for ETR-3 using sequences identified by systematic evolution of ligands by exponential enrichment. Mol Cell Biol (2005) 2.03
Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res (2008) 1.98
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res (2006) 1.98
Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development. Dev Dyn (2005) 1.95
Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A (2008) 1.94
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res (2011) 1.84
Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther (2011) 1.82
MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum Mol Genet (2006) 1.77
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem (2004) 1.57
Antisense oligonucleotide-based therapeutics for cancer. Oncogene (2003) 1.54
Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry (2010) 1.50
Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein. RNA (2003) 1.47
CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet (2010) 1.44
CELF6, a member of the CELF family of RNA-binding proteins, regulates muscle-specific splicing enhancer-dependent alternative splicing. J Biol Chem (2004) 1.43
Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res (2012) 1.42
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem (2004) 1.41
Global regulation of alternative splicing during myogenic differentiation. Nucleic Acids Res (2010) 1.39
Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy. Mol Cell Biol (2005) 1.35
Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet (2010) 1.35
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res (2010) 1.35
Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques (2006) 1.30
Antisense reduction of tau in adult mice protects against seizures. J Neurosci (2013) 1.29
A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res (2006) 1.26
Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol (2012) 1.25
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res (2013) 1.23
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat Chem Biol (2012) 1.22
Alternative splicing in disease. Adv Exp Med Biol (2007) 1.22
MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev (2010) 1.22
Identification of MBNL1 and MBNL3 domains required for splicing activation and repression. Nucleic Acids Res (2010) 1.20
PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest (2009) 1.19
Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol (2006) 1.16
ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. Nucleic Acids Res (2004) 1.16
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med (2012) 1.14
Identification of CELF splicing activation and repression domains in vivo. Nucleic Acids Res (2005) 1.12
Multiple domains control the subcellular localization and activity of ETR-3, a regulator of nuclear and cytoplasmic RNA processing events. J Cell Sci (2004) 1.11
RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res (2012) 1.11
Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ERalpha transcriptional activity and MCF-7 proliferation. Mol Endocrinol (2002) 1.09
Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol (2011) 1.09
Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med (2011) 1.07
Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. Biol Chem (2011) 1.03
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol (2013) 1.01
Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation. J Biol Chem (2008) 1.00
Polypurine-repeat-containing RNAs: a novel class of long non-coding RNA in mammalian cells. J Cell Sci (2010) 0.99
Widespread recognition of 5' splice sites by noncanonical base-pairing to U1 snRNA involving bulged nucleotides. Genes Dev (2012) 0.98
CUGBP2 directly interacts with U2 17S snRNP components and promotes U2 snRNA binding to cardiac troponin T pre-mRNA. Nucleic Acids Res (2009) 0.97
HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res (2006) 0.96
Sequence-dependent cytotoxicity of second-generation oligonucleotides. Nucleic Acids Res (2004) 0.95
Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res (2004) 0.94
Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol (2014) 0.92
Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy. Proc Natl Acad Sci U S A (2013) 0.92
Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open Biol (2012) 0.91
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. J Med Chem (2005) 0.90
Modulation of LMNA splicing as a strategy to treat prelamin A diseases. J Clin Invest (2016) 0.90
Expression, localization and tau exon 10 splicing activity of the brain RNA-binding protein TNRC4. Hum Mol Genet (2007) 0.90
Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J Med Chem (2006) 0.89
Pathological impact of SMN2 mis-splicing in adult SMA mice. EMBO Mol Med (2013) 0.88
Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides. Hum Mol Genet (2009) 0.88
Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum (2009) 0.87
Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue. J Med Chem (2010) 0.86
Myotonic dystrophy: discussion of molecular basis. Adv Exp Med Biol (2002) 0.85
TSUNAMI: an antisense method to phenocopy splicing-associated diseases in animals. Genes Dev (2012) 0.84
Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res (2013) 0.84